Table 4.

mtDNA copy number in relation to the risk of colorectal cancer with pre-diagnostic blood samples by gender, colorectal cancer subsite, and duration between blood draw and cancer diagnosis

mtDNA copy number in quartile
Subgroups1st quartile2nd quartile3rd quartile4th quartileP for curvilinearity
MenCases/controls28/9512/9511/9541/94
ORa (95% CI)3.72 (1.02–13.54)1.002.10 (0.51–8.58)8.74 (2.52–30.34)0.005
WomenCases/controls33/12410/12416/12417/123
ORa (95% CI)4.83 (1.42–16.38)1.002.37 (0.65–8.58)2.69 (0.75–9.69)0.001
Colon cancerCases/controls44/21913/21916/21929/217
ORb (95% CI)3.36 (1.24–9.08)1.001.42 (0.48–4.23)2.94 (1.06–8.15)0.001
Rectal cancerCases/controls17/2199/21911/21929/219
ORb (95% CI)3.17 (1.01–10.02)1.001.39 (0.42–4.57)7.64 (2.56–22.76)<0.001
 <3 yearscCases/controls48/21916/21916/21941/217
ORb (95% CI)2.81 (1.09–7.25)1.001.08 (0.37–3.13)5.27 (2.06–13.50)<0.001
 3+ yearscCases/controls13/2196/21911/21917/217
ORb (95%CI)5.23 (1.42–19.33)1.002.65 (0.72–9.69)3.77 (1.08–13.17)0.03
  • aAdjusted for age at sample collection, BMI, smoking, alcohol drinking, diabetes, weekly moderate or vigorous physical activity, and batch number.

  • bAdjusted for age at sample collection, gender, BMI, smoking, alcohol drinking, diabetes, weekly moderate or vigorous physical activity, and batch number.

  • cNumber of years between blood draw and cancer diagnosis.